sacituzumab (anti-trop-2)

Sacituzumab is a humanized IgG1 monoclonal antibody utilized in the synthesis of antibody-active small-molecule couplings (naked antibody to Sacituzumab govitecan). It exhibits potential antitumor activity and is employed in tumor research.

TL033 TFA is a component of an antibody-drug conjugate (drug-linker conjugate for ADC). It comprises a linker and a bioactive small molecule toxin. TL033 TFA can be conjugated with the antibody Sacituzumab (anti-Trop-2) to synthesize BT001021, which exhibits anticancer activity against various cancers, including breast cancer, non-small cell lung cancer (NSCLC), and gastric cancer.

TL033 forms a component of an antibody-drug conjugate (ADC) as a drug-linker conjugate. It comprises a linker and a bioactive small molecule toxin. TL033 can be conjugated with the Sacituzumab antibody (anti-Trop-2) to synthesize BT001021, which exhibits anticancer activity against various cancers, including breast cancer, non-small cell lung cancer (NSCLC), and gastric cancer.